Navigation Links
Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
Date:4/15/2009

Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced that Lee Ann Laurent-Applegate PD & MER has joined Stemedica's Scientific Advisory Board. In this capacity, she will help Stemedica advance the clinical development of a proprietary whole cell bio-processing and cellular delivery system for burn and wound management.

San Diego, CA (PRWEB) April 15, 2009 -- Stemedica Cell Technologies, Inc., ("Stemedica"), a leader in adult stem cell research and manufacturing, announced that Lee Ann Laurent-Applegate PD & MER has joined Stemedica's Scientific Advisory Board. In this capacity, she will help Stemedica advance the clinical development of a proprietary whole cell bio-processing and cellular delivery system for burn and wound management.

Dr. Applegate is Head of the Cellular Therapy Unit for Swiss Hospital Centre Hospitalier Universitaire Vaudois ("CHUV") which is associated with the University of Lausanne in Lausanne, Switzerland. Dr. Applegate has served in various leadership positions at CHUV for the past nineteen years and is regarded as one of the world's foremost authorities in the administration of cellular delivery systems, having worked with the application of proprietary cell applications for burns and wound care since 1991. Dr. Applegate's current research interests center around wound healing and tissue repair through the dynamic application of proteins and tissue engineering.

Working in conjunction with dermatologist/ angiologist Dr. Albert-Adrien Ramelet, and Dr. Wassim Raffoul, head of the CHUV Burn Center, Dr. Applegate has completed both Phase I and Phase II clinical trials in Switzerland for the treatment of pediatric burns and c
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Renowned Stem Cell Researcher Files Study Results With Stemedica
2. CIRM Completes Briefing Visit to Stemedica Cell Technologies
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
6. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
7. New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel
8. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
9. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
10. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
11. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
(Date:11/23/2009)...n a provocative new study, a University of Utah sc...s the major cause of global warming cannot be st...ociety builds the equivalent of one new nuclear po...here will be any substantial near-term departure f...de emission rates," says the new paper by Tim Garr...
(Date:11/23/2009)...PRNewswire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasd...vember27,2009astheex-dividenddateforits$200million...itizationtransactioncompletedonNovember2,2009.Thed...sofrecordontherecorddate,December1,2009.NASDAQhass...pershareofcommonstockforpurposesoftheex-dividendda...
(Date:11/23/2009)...-ImmuneDesignC or p.(IDC)announcedtodaythatDr.Bruc...erhasasuccessfultrackrec or dinbiotechnologyexecut...ratZymoGenetics,inSeattle,WAandChiefScientificOffi...o: http://www.newscom.com/cgi-bin/prnh/20091123/SF...ecutiveOfficercommented,"IamdelightedtowelcomeDr.B...
(Date:11/23/2009)...-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq: C...iring,developingandcommercializingsignificantprodu...ayannouncedthatCraigA.Collard,PresidentandChiefExe...the21stAnnualPiperJaffrayHealthCareConferenceat3:3...otelinNewYorkCity. ,, Aliveaudioandarchivedwebc...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2
...Management Changes Announced, NEW YORK, March 5 ...nnounced that the company,s Board of Directors,has...chief financial,officer, effective March 31, 2008....recting and managing the company,s fiscal operatio...the organization and its,subsidiaries. Andrew Bonf...
...se II study of 20 patients reported in Annals of O....,(CTI) (Nasdaq: CTIC ; MTA) today announced the ...lts of a limited phase II study of CHOP chemothera...d prednisone) followed by,administration of Zevali...0,years of age or older) with previously untreated...
...lbaum, assistant professor of electrical and compu... received the prestigious Faculty Early Career Dev...n for his pioneering research in the exciting next... This emerging field focuses on harnessing the mag...ctronics ranging from computers to cell phones tha...
Other Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4UD's Appelbaum wins NSF Career Award for research on silicon spintronics 2UD's Appelbaum wins NSF Career Award for research on silicon spintronics 3
(Date:11/24/2009)...rs to understanding how sounds associated with Nav...l or if they hear it at all. , The same type of...ses to detect flaws in the space shuttle,s behemot... peek inside the giant head of a whale. The scans ...of a whale,s hearing anatomy using a breakthrough ...
(Date:11/24/2009)...bby arteries from collapsing have been true life-s...onger needed -- once the arteries are strengthened... no choice but to leave them in place. , Prof. M...t of Biomedical Engineering has developed a new pa...re they,re needed, then dissolves. , "Our new co...
(Date:11/24/2009)... of Medical Toxicology (ACMT) have signed an agree...rnal of Medical Toxicology (JMT), the official jo...s previously published by the University of Pennsy...ogy , an international, peer-reviewed journal, is ... medical toxicology. The quarterly journal focuse...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 1Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 8Carondelet St Marys Medical Plaza II Opens In Tucson 55314 1MicroRNA in human saliva may help diagnose oral cancer 9696 1
...ced a major expansion of a lingua franca used to d...s. The expansion provides terms that scientists c...hen a pathogenic or beneficial microbe encounters ...r developing new interventions for preventing infe...g or encouraging the presence of beneficial microb...
...s of other individuals in order to cooperate in co...we humans take for granted. But, according to evol... Institute in Germany, this ability is present in ...April issue of Current Directions in Psychological... gaze and face orientation to monitor others, beha...
...may explain why Graves?disease (GD) attacks the mu... bulge painfully from their sockets, as in the lat...s Stein Eye Institute and Harbor-UCLA Medical Cent...cells of GD patients?immune systems. Reported Mar... deepen understanding of how the autoimmune disord...
Other Biology News:Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Man's best friend lends insight into human evolution 2UCLA study uncovers clues for why Graves' disease attacks the eyes 2
Viraffinity 100 from Biotech Support Group
Tumor Suppressor Sampler Kit from BD Biosciences Pharmingen
Mouse Anti-Synapsin I Monoclonal Antibody, Unconjugated, Clone 223 from IMGENEX
Slide Chambers from Novagen
Biology Products: